Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089193 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
A Phase 2 study, sponsored by Craig L Slingluff, Jr.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00089193 is a Phase 2 study that has completed, run by Craig L Slingluff, Jr.
The verdict
NCT00089193, a Phase 2 study, has completed, sponsored by Craig L Slingluff, Jr.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may cause a stronger immune response and kill more tumor cells. PURPOSE: This randomized phase II trial is studying vaccine therapy and sargramostim to see how well they work compared to vaccine therapy alone in treating patients with stage II B, stage IIC, stage III, or stage IV melanoma.
Interventions
- BIOLOGICAL sargramostim
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL multi-epitope melanoma peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00089193
The ClinicalTrials.gov registry entry for NCT00089193 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Craig L Slingluff, Jr, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which sargramostim is the first listed.
NCT00089193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00089193 about?
NCT00089193 is a clinical study titled "Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may cause a stronger immune response and k...
What is the current status of trial NCT00089193?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-09.
What interventions are being tested in trial NCT00089193?
The interventions under investigation include: sargramostim (BIOLOGICAL), incomplete Freund's adjuvant (BIOLOGICAL), multi-epitope melanoma peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00089193?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.